The tumour suppressor CYLD negatively regulates NF-κB signalling by deubiquitination (original) (raw)
- Letter
- Published: 14 August 2003
- Christine Chable-Bessia2,
- Giuseppina Cantarella1,3,
- Alain Israël2,
- David Wallach1 &
- …
- Gilles Courtois2
Nature volume 424, pages 801–805 (2003)Cite this article
- 5490 Accesses
- 854 Citations
- 7 Altmetric
- Metrics details
Abstract
NF-κB transcription factors have key roles in inflammation, immune response, oncogenesis and protection against apoptosis1,2. In most cells, these factors are kept inactive in the cytoplasm through association with IκB inhibitors. After stimulation by various reagents, IκB is phosphorylated by the IκB kinase (IKK) complex3 and degraded by the proteasome, allowing NF-κB to translocate to the nucleus and activate its target genes. Here we report that CYLD, a tumour suppressor that is mutated in familial cylindromatosis4, interacts with NEMO, the regulatory subunit of IKK5,6. CYLD also interacts directly with tumour-necrosis factor receptor (TNFR)-associated factor 2 (TRAF2), an adaptor molecule involved in signalling by members of the family of TNF/nerve growth factor receptors. CYLD has deubiquitinating activity that is directed towards non-K48-linked polyubiquitin chains, and negatively modulates TRAF-mediated activation of IKK, strengthening the notion that ubiquitination is involved in IKK activation by TRAFs and suggesting that CYLD functions in this process. Truncations of CYLD found in cylindromatosis result in reduced enzymatic activity, indicating a link between impaired deubiquitination of CYLD substrates and human pathophysiology.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Additional access options:
Similar content being viewed by others
References
- Karin, M. & Ben-Neriah, B. Phosphorylation meets ubiquitination: the control of NF-κB activity. Annu. Rev. Immunol. 18, 621–663 (2000)
Article CAS Google Scholar - Li, Q. & Verma, I. M. NF-κB regulation in the immune system. Nature Rev. Immunol. 2, 725–734 (2002)
Article CAS Google Scholar - Israël, A. The IKK complex: an integrator of all signals that activate NF-κB? Trends Cell. Biol. 10, 129–133 (2000)
Article Google Scholar - Bignell, G. R. et al. Identification of the familial cylindromatosis tumour-suppressor gene. Nature Genet. 25, 160–165 (2000)
Article CAS Google Scholar - Yamaoka, S. et al. Complementation cloning of NEMO, a component of the IκB kinase complex essential for NF-κB activation. Cell 93, 1231–1240 (1998)
Article CAS Google Scholar - Rothwarf, D. M., Zandi, E., Natoli, G. & Karin, M. IKK-γ is an essential regulatory subunit of the IκB kinase complex. Nature 395, 297–300 (1998)
Article ADS CAS Google Scholar - Courtois, G., Smahi, A. & Israël, A. NEMO/IKKγ: linking NF-κB to human disease. Trends Mol. Med. 7, 427–430 (2001)
Article CAS Google Scholar - Ye, H., Park, Y. C., Kreishman, M., Kieff, E. & Wu, H. The structural basis for the recognition of diverse receptor sequences by TRAF2. Mol. Cell 4, 321–330 (1999)
Article CAS Google Scholar - Wilkinson, K. D. Regulation of ubiquitin-dependent processes by deubiquitinating enzymes. FASEB J. 11, 1245–1256 (1997)
Article CAS Google Scholar - D'Andrea, A. & Pellman, D. Deubiquitinating enzymes: a new class of biological regulators. Crit. Rev. Biochem. Mol. Biol. 33, 337–352 (1998)
Article CAS Google Scholar - Deng, L. et al. Activation of the IκB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell 103, 351–361 (2000)
Article CAS Google Scholar - Wang, C. et al. TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature 412, 346–351 (2001)
Article ADS CAS Google Scholar - Shi, C. S. & Kehrl, J. H. TNF-induced GCKR and SAPK activation depends upon the E2/E3 complex Ubc13–Uev1A/TRAF2. J. Biol. Chem. 278, 15429–15434 (2003)
Article CAS Google Scholar - Maniatis, T. A ubiquitin ligase complex essential for the NF-κB, Wnt/Wingless, and Hedgehog signaling pathways. Genes Dev. 13, 505–510 (1999)
Article CAS Google Scholar - Pomerantz, J. L. & Baltimore, D. Two pathways to NF-κB. Mol. Cell 10, 693–695 (2002)
Article CAS Google Scholar - Chu, Z. L., DiDonato, J. A., Hawiger, J. & Ballard, D. W. The tax oncoprotein of human T-cell leukemia virus type 1 associates with and persistently activates IκB kinases containing IKKα and IKKβ. J. Biol. Chem. 273, 15891–15894 (1998)
Article CAS Google Scholar - Mercurio, F. et al. IKK-1 and IKK-2: cytokine-activated IκB kinases essential for NF-κB activation. Science 278, 860–866 (1997)
Article ADS CAS Google Scholar - McManus, M. T. & Sharp, P. A. Gene silencing in mammals by small interfering RNAs. Nature Rev. Genet. 3, 737–747 (2002)
Article CAS Google Scholar - Brummelkamp, T. R., Bernards, R. & Agami, R. A system for stable expression of short interfering RNAs in mammalian cells. Science 296, 550–553 (2002)
Article ADS CAS Google Scholar - Borodovsky, A. et al. Chemistry-based functional proteomics reveals novel members of the deubiquitinating enzyme family. Chem. Biol. 9, 1149–1159 (2002)
Article CAS Google Scholar - Karin, M., Cao, Y., Greten, F. R. & Li, Z. W. NF-κB in cancer: from innocent bystander to major culprit. Nature Rev. Cancer 2, 301–310 (2002)
Article CAS Google Scholar - Döffinger, R. et al. X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-κB signaling. Nature Genet. 27, 277–85 (2001)
Article Google Scholar
Acknowledgements
We thank R. Agami for the pSUPER vector and advice; R. Beyaert, C. J. Kirschning, M. Krönke, F. Mercurio, K.-I. Nakayama, M. Rowe and M. Treier for plasmids; T. Goncharov, S. Leu, D. Landstein, M. Pasparakis, F. Agou and S. Yamaoka for discussions and support; and I. Beilis and T. Lopez for technical assistance. This work was supported in part by grants from Inter-Lab Ltd, from Ares Trading SA and from the Alfred and Ann Goldstein Foundation to A.K., G.Ca amd D.W., from PTR Pasteur/Necker to G.Co, and from ‘La ligue Nationale contre le Cancer’ (équipe labellisée) to A.I. A.K. was supported by a postdoctoral fellowship from ‘La ligue Nationale contre le Cancer’.
Author information
Authors and Affiliations
- Department of Biological Chemistry, The Weizmann Institute of Science, 76100, Rehovot, Israel
Andrew Kovalenko, Giuseppina Cantarella & David Wallach - Unité de Biologie Moléculaire de l'Expression Génique, CNRS URA 2582, Institut Pasteur, 75015, Paris, France
Andrew Kovalenko, Christine Chable-Bessia, Alain Israël & Gilles Courtois - Department of Experimental and Clinical Pharmacology, University of Catania School of Medicine, I-95125, Catania, Italy
Giuseppina Cantarella
Authors
- Andrew Kovalenko
You can also search for this author inPubMed Google Scholar - Christine Chable-Bessia
You can also search for this author inPubMed Google Scholar - Giuseppina Cantarella
You can also search for this author inPubMed Google Scholar - Alain Israël
You can also search for this author inPubMed Google Scholar - David Wallach
You can also search for this author inPubMed Google Scholar - Gilles Courtois
You can also search for this author inPubMed Google Scholar
Corresponding author
Correspondence toDavid Wallach.
Ethics declarations
Competing interests
The authors declare that they have no competing financial interests.
Supplementary information
Rights and permissions
About this article
Cite this article
Kovalenko, A., Chable-Bessia, C., Cantarella, G. et al. The tumour suppressor CYLD negatively regulates NF-κB signalling by deubiquitination.Nature 424, 801–805 (2003). https://doi.org/10.1038/nature01802
- Received: 17 March 2003
- Accepted: 20 May 2003
- Issue Date: 14 August 2003
- DOI: https://doi.org/10.1038/nature01802